Every 424B that Hoth Therapeutics, Inc. (HOTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HOTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOTH filings page.
Rocket One Inc. amends its prior prospectus supplements to increase the amount available for sale under its Sales Agreement with H.C. Wainwright & Co., LLC. This Amendment No. 2 makes available up to an additional $6,829,000 of common stock for sale pursuant to the Sales Agreement dated November 8, 2024.
The filing states that the company previously offered and sold 8,124,155 shares for gross proceeds of approximately $9.27 million under the Sales Agreement. It reports 22,322,326 shares outstanding and a public float market value held by non-affiliates of $48,326,580 based on 21,768,730 shares held by non-affiliates at a closing price of $2.22 per share on June 2, 2026. The prospectus cites eligibility under General Instruction I.B.6 of Form S-3 to offer up to approximately $6,829,000 in additional shares.
Rocket One Inc. amends its prospectus supplement to increase the amount available under its at-the-market Sales Agreement with H.C. Wainwright & Co., LLC. The company is offering up to an additional $2,661,176 of common stock for sale under the Sales Agreement.
The amendment states the company previously sold 6,824,327 shares for gross proceeds of approximately $6.6 million under the Sales Agreement. It reports 21,022,498 shares outstanding, with 20,468,902 shares held by non-affiliates, and a public-float market value of $27,837,706 based on a $1.36 per-share closing price on May 27, 2026. The filing confirms eligibility under General Instruction I.B.6 of Form S-3 to sell up to the additional amount.
Hoth Therapeutics, Inc. is offering, on an at-the-market basis, common stock having an aggregate offering price of up to $1,555,000 through H.C. Wainwright & Co., LLC as sales agent under a Sales Agreement dated November 8, 2024.
Sales may occur on Nasdaq or other U.S. trading markets, in negotiated transactions or directly to the agent. The company will pay a 3.0% commission to the sales agent. The prospectus supplement cites 19,127,643 shares outstanding and a public float of approximately $21,176,693 based on March 11, 2026 pricing used for the float calculation.
Hoth Therapeutics, Inc. is offering 2,857,144 shares of common stock at an offering price of $0.70 per share to several institutional investors pursuant to a securities purchase agreement dated April 1, 2026. The gross proceeds from the public portion of the offering are approximately $2.0 million, before placement agent fees and expenses.
The company is conducting a concurrent private placement of unregistered warrants to purchase up to 2,857,144 shares (one warrant per share sold) exercisable beginning six months from issuance for five years at an exercise price of $0.85 per share. Delivery of the shares is expected on or about April 2, 2026, subject to customary closing conditions.
Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C. Wainwright. The company is now offering up to $4,821,200 of common stock under the existing ATM agreement, after effectiveness and pursuant to General Instruction I.B.6 of Form S-3.
Since launching the ATM, Hoth has sold 3,919,559 shares for gross proceeds of about $5.5 million. The company cites a public float of approximately $30,968,682, which caps primary offerings at one-third of float over any 12-month period; the new $4,821,200 capacity reflects that limit. Shares trade on Nasdaq as “HOTH,” with a last reported sale price of $1.28 on November 12, 2025.